JP2018507877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507877A5 JP2018507877A5 JP2017546949A JP2017546949A JP2018507877A5 JP 2018507877 A5 JP2018507877 A5 JP 2018507877A5 JP 2017546949 A JP2017546949 A JP 2017546949A JP 2017546949 A JP2017546949 A JP 2017546949A JP 2018507877 A5 JP2018507877 A5 JP 2018507877A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1128/CHE/2015 | 2015-03-09 | ||
| IN1128CH2015 | 2015-03-09 | ||
| PCT/IB2016/051302 WO2016142855A2 (en) | 2015-03-09 | 2016-03-08 | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507877A JP2018507877A (ja) | 2018-03-22 |
| JP2018507877A5 true JP2018507877A5 (cg-RX-API-DMAC10.html) | 2020-04-30 |
| JP6789962B2 JP6789962B2 (ja) | 2020-11-25 |
Family
ID=56879301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546949A Expired - Fee Related JP6789962B2 (ja) | 2015-03-09 | 2016-03-08 | ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11186576B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3268000B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6789962B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN107530329B (cg-RX-API-DMAC10.html) |
| CA (1) | CA2978170C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2899196T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016142855A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015154022A1 (en) * | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2016142855A2 (en) * | 2015-03-09 | 2016-09-15 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| ES2994013T3 (en) | 2017-07-28 | 2025-01-15 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| TWI703149B (zh) | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| HRP20241119T1 (hr) * | 2018-03-29 | 2024-11-22 | Takeda Pharmaceutical Company Limited | Heterociklički spoj |
| IL299105B2 (en) * | 2018-04-11 | 2024-02-01 | Lead Discovery Center Gmbh | Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine |
| MX2020010675A (es) | 2018-04-11 | 2020-10-28 | Qurient Co Ltd | Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina. |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| EA039950B1 (ru) * | 2018-07-20 | 2022-03-31 | Эли Лилли Энд Компани | Соединения, пригодные для ингибирования cdk7 |
| CN110835345A (zh) * | 2018-08-17 | 2020-02-25 | 中国科学院上海药物研究所 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
| MA54092A (fr) | 2018-10-30 | 2021-09-08 | Kronos Bio Inc | Composés, compositions et procédés de modulation de l'activité de cdk9 |
| US20220144841A1 (en) * | 2019-03-13 | 2022-05-12 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
| CN112125908B (zh) * | 2019-06-25 | 2023-11-03 | 隆泰申医药科技(南京)有限公司 | Cdk激酶抑制剂、其制备方法、药物组合物和应用 |
| BR112022009881A2 (pt) * | 2019-11-22 | 2022-10-11 | Univ California | Inibidores de caspase 6 e usos dos mesmos |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| EP4079733A1 (en) * | 2019-12-20 | 2022-10-26 | Evopoint Biosciences Co., Ltd. | Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| CN111393447B (zh) * | 2020-05-14 | 2021-01-15 | 苏州信诺维医药科技有限公司 | 一种嘧啶并吡唑类化合物、其制备方法及应用 |
| TWI783480B (zh) | 2020-05-27 | 2022-11-11 | 美商美國禮來大藥廠 | 用於抑制cdk7之化合物 |
| CN114133394B (zh) * | 2020-08-12 | 2023-12-08 | 赛诺哈勃药业（成都）有限公司 | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 |
| CN114075205A (zh) * | 2020-08-12 | 2022-02-22 | 隆泰申医药科技(南京)有限公司 | Cdk激酶抑制剂、其制备方法、药物组合物和应用 |
| US20240217960A1 (en) * | 2021-04-09 | 2024-07-04 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| CN115340524B (zh) * | 2021-05-14 | 2024-05-28 | 重庆博腾制药科技股份有限公司 | 一种(s)-去甲烟碱甲基化制备(s)-尼古丁的方法 |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| CN113801119B (zh) * | 2021-08-30 | 2022-09-30 | 新乡医学院 | 一种吡唑并[1,3,5]三嗪类化合物的合成方法 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| CN114181217B (zh) * | 2022-01-10 | 2022-12-27 | 陕西师范大学 | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
| WO2023227125A1 (zh) * | 2022-05-26 | 2023-11-30 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| CN119790056A (zh) * | 2022-09-30 | 2025-04-08 | 楚浦创制（武汉）医药科技有限公司 | 三并环类衍生物、药物组合物以及应用 |
| WO2024125532A1 (zh) * | 2022-12-12 | 2024-06-20 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2025040170A1 (zh) * | 2023-08-24 | 2025-02-27 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| CN119707984A (zh) * | 2023-09-28 | 2025-03-28 | 中国科学院上海药物研究所 | 吡唑并三嗪及吡唑并嘧啶衍生物、其制备方法、药物组合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| PL353455A1 (en) | 1999-08-12 | 2003-11-17 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
| JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7517882B2 (en) | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| JP2010529140A (ja) * | 2007-06-05 | 2010-08-26 | エモリー・ユニバーシテイ | サイクリン依存性キナーゼの選択的阻害剤 |
| WO2010003133A2 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| FR2943058B1 (fr) | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| EP2634190A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP2634189A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2014238443A1 (en) * | 2013-03-15 | 2015-07-30 | Celgene Car Llc | MK2 inhibitors and uses thereof |
| WO2015154022A1 (en) | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2016142855A2 (en) * | 2015-03-09 | 2016-09-15 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| AU2016272908B2 (en) * | 2015-06-04 | 2021-05-06 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as CDK inhibitors |
-
2016
- 2016-03-08 WO PCT/IB2016/051302 patent/WO2016142855A2/en not_active Ceased
- 2016-03-08 JP JP2017546949A patent/JP6789962B2/ja not_active Expired - Fee Related
- 2016-03-08 US US15/557,028 patent/US11186576B2/en not_active Expired - Fee Related
- 2016-03-08 CN CN201680014422.1A patent/CN107530329B/zh active Active
- 2016-03-08 CA CA2978170A patent/CA2978170C/en active Active
- 2016-03-08 ES ES16761176T patent/ES2899196T3/es active Active
- 2016-03-08 EP EP16761176.3A patent/EP3268000B1/en active Active
-
2021
- 2021-10-01 US US17/492,282 patent/US20220281871A1/en not_active Abandoned